Literature DB >> 15831368

Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension.

Sandra Blanco1, Manuel Vaquero, Carmen Gómez-Guerrero, Dolores López, Jesús Egido, Ramón Romero.   

Abstract

BACKGROUND: Experimental findings suggest that the obese Zucker rat (OZR) is a model of type 2 diabetes-related nephropathy with several metabolic abnormalities. However, the exact mechanisms by which these factors cause early glomerulosclerosis and proteinuria remain unclear. Furthermore, structural abnormalities and regulation of podocytes have recently emerged as prominent underlying factors in proteinuria. The aim of this study was to evaluate the potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in an experimental model of type 2 diabetes mellitus.
METHODS: We used OZR to evaluate some of the pathogenic mechanisms and the effects of two drugs, an angiotensin-converting enzyme (ACE) inhibitor (quinapril) and a statin (atorvastatin), involved in the development of proteinuria and especially podocyte damage. We studied glomerular and tubulointerstitial injury by assessing inflammation mediators (murine monoclonal antibody against CD68 [ED1+], interleukin-8 [IL-8], interferon-gamma-inducible protein 10 [IP-10]) and podocyte damage markers using desmin staining and electron microscopy.
RESULTS: Glomerular lesions were correlated with cholesterol (r = 0.676), proteinuria (r = 0.804), triglycerides (r = 0.593), insulin (r = 0.345), creatinine (r = 0.266), and glucose (r = 0.245). In addition, podocytes from OZR showed positive staining for desmin. Use of the ACE inhibitor quinapril normalized proteinuria, cholesterol levels, glomerular lesions, and podocyte morphology. In contrast, atorvastatin ameliorated but did not normalize renal damage, with a partial reduction in desmin staining and podocyte morphology. Treatment with both drugs resulted in only a slight reduction in IL-8 and IP-10 in the tubulointerstitium.
CONCLUSIONS: In the OZR, cholesterol was an important determinant of renal injury. Most notably, glomerulosclerosis in the OZR Is characterized by early podocyte damage and tubulointerstitial injury. In addition, our findings showed that quinapril primarily normalized podocyte morphology, whereas atorvastatin ameliorated renal lesions through the diminution of lipids and by its lipid-independent pleiotropic effect.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15831368     DOI: 10.1016/j.amjhyper.2004.10.034

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  19 in total

1.  Fluvastatin inhibits angiotensin II-induced nuclear factor kappa B activation in renal tubular epithelial cells through the p38 MAPK pathway.

Authors:  Ping Gao; Xiaoyan Wu; Hua Shui; Ruhan Jia
Journal:  Mol Biol Rep       Date:  2011-09-24       Impact factor: 2.316

2.  Early podocyte injury and elevated levels of urinary podocyte-derived extracellular vesicles in swine with metabolic syndrome: role of podocyte mitochondria.

Authors:  Li-Hong Zhang; Xiang-Yang Zhu; Alfonso Eirin; Arash Aghajani Nargesi; John R Woollard; Adrian Santelli; In O Sun; Stephen C Textor; Lilach O Lerman
Journal:  Am J Physiol Renal Physiol       Date:  2019-05-01

Review 3.  Podocytopathy in diabetes: a metabolic and endocrine disorder.

Authors:  Ana Diez-Sampedro; Oliver Lenz; Alessia Fornoni
Journal:  Am J Kidney Dis       Date:  2011-06-29       Impact factor: 8.860

Review 4.  Role of the Renal Microcirculation in Progression of Chronic Kidney Injury in Obesity.

Authors:  Alejandro R Chade; John E Hall
Journal:  Am J Nephrol       Date:  2016-10-22       Impact factor: 3.754

Review 5.  Lipids and diabetic renal disease.

Authors:  Mark E Cooper; Karin A M Jandeleit-Dahm
Journal:  Curr Diab Rep       Date:  2005-12       Impact factor: 4.810

Review 6.  Interaction of aldosterone and extracellular volume in the pathogenesis of obesity-associated kidney disease: a narrative review.

Authors:  Andrew S Bomback; Philip J Klemmer
Journal:  Am J Nephrol       Date:  2009-03-20       Impact factor: 3.754

7.  Simvastatin and tempol protect against endothelial dysfunction and renal injury in a model of obesity and hypertension.

Authors:  Sarah F Knight; Jianghe Yuan; Siddhartha Roy; John D Imig
Journal:  Am J Physiol Renal Physiol       Date:  2009-11-11

8.  Effect of simvastatin on the expression of nephrin, podocin, and vascular endothelial growth factor (VEGF) in podocytes of diabetic rat.

Authors:  Shujun Chen; Haiping Chen; Qi Liu; Qing Ma
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 9.  Dual effects of RAS blockade on blood pressure and podocyte function.

Authors:  Jochen Reiser; Peter Mundel
Journal:  Curr Hypertens Rep       Date:  2007-11       Impact factor: 5.369

10.  Smoking in diabetic nephropathy: sparks in the fuel tank?

Authors:  Vishal Arvind Chakkarwar
Journal:  World J Diabetes       Date:  2012-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.